{
    "clinical_study": {
        "@rank": "90706", 
        "acronym": "RAD HF", 
        "arm_group": [
            {
                "arm_group_label": "Ranolazine", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of\n      recurrent atrial fibrillation in post-cardioversion patients with heart failure and\n      preserved ejection fraction."
        }, 
        "brief_title": "The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Heart Failure"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Heart Failure", 
                "Heart Failure, Diastolic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant female > 18 years of age;\n\n          -  Documentation of heart failure and who are in NYHA class II or III;\n\n          -  Documented history of symptomatic AF < 6 months in duration at the time of\n             presentation, currently in AF at the time of the external electrical cardioversion,\n             and successfully restored to normal sinus rhythm;\n\n          -  Percutaneous coronary intervention (PCI) patients who can be placed on\n             anticoagulation with warfarin post-cardioversion (and not on rivaroxaban or\n             dabigatran);\n\n          -  Demonstration of preserved ejection fraction (EF) by echocardiography;\n\n          -  Echocardiographic evidence of impaired diastolic filling.\n\n        Exclusion Criteria:\n\n          -  Known history of permanent or long-standing AF (> 6 months);\n\n          -  Other acutely reversible causes of AF, including but not limited to: hyperthyroidism,\n             pericarditis, myocarditis or pulmonary embolism;\n\n          -  Known history of cirrhosis;\n\n          -  NYHA Class IV;\n\n          -  Myocardial Infarction, unstable angina, or coronary artery bypass graft surgery\n             within three months prior to screening;\n\n          -  Percutaneous coronary intervention (PCI) within 4 weeks prior to screening, if these\n             patients need to be placed on rivaroxaban or dabigatran post-cardioversion;\n\n          -  Clinically significant valvular disease;\n\n          -  Clinically significant pulmonary disease;\n\n          -  Stroke within 3 months prior to screening;\n\n          -  Creatinine clearance < 30 mL/min as calculated by Cockcroft-Gault formula;\n\n          -  Use of anti-arrhythmic drugs (Class Ia or IIIc) within 3 months prior to screening;\n\n          -  Concurrent use of drugs considered strong inhibitors of CYP3A;\n\n          -  Concurrent use of drugs considered as CYP3A inducers;\n\n          -  Prior treatment with ranolazine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887353", 
            "org_study_id": "1024475"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ranolazine", 
                "description": "Patients will take ranolazine 1000 mg tablets twice daily", 
                "intervention_name": "Ranolazine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ranolazine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "atrial fibrillation", 
            "heart failure", 
            "ranolazine", 
            "cardioversion", 
            "persistent AF", 
            "paroxysmal AF"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "contact": {
                "email": "Jared.Bunch@imail.org", 
                "last_name": "T. Jared Bunch, MD", 
                "phone": "801-507-4701"
            }, 
            "facility": {
                "address": {
                    "city": "Murray", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84107-5701"
                }, 
                "name": "Intermountain Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "T. Jared Bunch, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Brian Crandall, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John D Day, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pete Weiss, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jeffrey Osborn, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Charles Mallendar, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion", 
        "overall_contact": {
            "email": "Jared.Bunch@imail.org", 
            "last_name": "T. Jared Bunch, MD", 
            "phone": "801-507-4701"
        }, 
        "overall_contact_backup": {
            "email": "Patti.Spencer@imail.org", 
            "last_name": "Patti Spencer", 
            "phone": "801-507-4778"
        }, 
        "overall_official": {
            "affiliation": "Intermountain Medical Center", 
            "last_name": "T. Jared Bunch, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to first AF recurrence", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887353"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Intermountain Health Care, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Intermountain Health Care, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}